Cargando…

Intraocular pressure and visual field changes in normal-tension glaucoma patients treated using either unoprostone or latanoprost: a prospective comparative study

PURPOSE: We conducted a prospective study in patients with normal-tension glaucoma (NTG) who received either isopropyl unoprostone or latanoprost. We compared the drugs in terms of their effects on intraocular pressure (IOP) and visual field loss progression over a 3-year period. STUDY DESIGN: Prosp...

Descripción completa

Detalles Bibliográficos
Autores principales: Takemoto, Daisuke, Higashide, Tomomi, Saito, Yoshiaki, Ohkubo, Shinji, Udagawa, Sachiko, Takeda, Hisashi, Sugiyama, Kazuhisa
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5589109/
https://www.ncbi.nlm.nih.gov/pubmed/28979091
http://dx.doi.org/10.2147/OPTH.S144344
_version_ 1783262277845123072
author Takemoto, Daisuke
Higashide, Tomomi
Saito, Yoshiaki
Ohkubo, Shinji
Udagawa, Sachiko
Takeda, Hisashi
Sugiyama, Kazuhisa
author_facet Takemoto, Daisuke
Higashide, Tomomi
Saito, Yoshiaki
Ohkubo, Shinji
Udagawa, Sachiko
Takeda, Hisashi
Sugiyama, Kazuhisa
author_sort Takemoto, Daisuke
collection PubMed
description PURPOSE: We conducted a prospective study in patients with normal-tension glaucoma (NTG) who received either isopropyl unoprostone or latanoprost. We compared the drugs in terms of their effects on intraocular pressure (IOP) and visual field loss progression over a 3-year period. STUDY DESIGN: Prospective, randomized controlled study. METHODS: We enrolled 48 patients with newly diagnosed NTG at Kanazawa University Hospital. Eligible patients were randomly allocated (1:1) to receive either unoprostone or latanoprost ophthalmic solutions. The primary outcomes were IOP changes and visual field deterioration within 36 months. Visual field changes were analyzed: the cumulative survival rates were calculated in terms of mean deviation, pattern standard deviation, and total deviation of the upper or lower hemi-visual field, each visual field sector, and guided progression analysis. In addition, we evaluated the progression of glaucomatous optic disc changes using fundus photography and confocal scanning laser ophthalmoscopy. RESULTS: The mean pretreatment IOP was 15.0±2.4 mmHg in the Unoprostone group and 15.2±1.9 mmHg in the Latanoprost group. The mean IOP during the treatment period was 13.7±2.3 mmHg in the Unoprostone group and 13.0±1.8 mmHg in the Latanoprost group. In both groups, the IOP decreased significantly (p<0.001) from baseline after treatment. The posttreatment IOP values were significantly lower in the Latanoprost group than in the Unoprostone group (p=0.023). Regarding the 3-year cumulative survival rate of visual field loss progression, there were no significant differences between groups in any parameters of the visual field or guided progression analysis. There were no significant differences between groups in disc changes. CONCLUSIONS: No significant differences were found between groups with regard to the visual field and structural progression in patients with NTG, although unoprostone was less effective than latanoprost in lowering the IOP.
format Online
Article
Text
id pubmed-5589109
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher Dove Medical Press
record_format MEDLINE/PubMed
spelling pubmed-55891092017-10-04 Intraocular pressure and visual field changes in normal-tension glaucoma patients treated using either unoprostone or latanoprost: a prospective comparative study Takemoto, Daisuke Higashide, Tomomi Saito, Yoshiaki Ohkubo, Shinji Udagawa, Sachiko Takeda, Hisashi Sugiyama, Kazuhisa Clin Ophthalmol Original Research PURPOSE: We conducted a prospective study in patients with normal-tension glaucoma (NTG) who received either isopropyl unoprostone or latanoprost. We compared the drugs in terms of their effects on intraocular pressure (IOP) and visual field loss progression over a 3-year period. STUDY DESIGN: Prospective, randomized controlled study. METHODS: We enrolled 48 patients with newly diagnosed NTG at Kanazawa University Hospital. Eligible patients were randomly allocated (1:1) to receive either unoprostone or latanoprost ophthalmic solutions. The primary outcomes were IOP changes and visual field deterioration within 36 months. Visual field changes were analyzed: the cumulative survival rates were calculated in terms of mean deviation, pattern standard deviation, and total deviation of the upper or lower hemi-visual field, each visual field sector, and guided progression analysis. In addition, we evaluated the progression of glaucomatous optic disc changes using fundus photography and confocal scanning laser ophthalmoscopy. RESULTS: The mean pretreatment IOP was 15.0±2.4 mmHg in the Unoprostone group and 15.2±1.9 mmHg in the Latanoprost group. The mean IOP during the treatment period was 13.7±2.3 mmHg in the Unoprostone group and 13.0±1.8 mmHg in the Latanoprost group. In both groups, the IOP decreased significantly (p<0.001) from baseline after treatment. The posttreatment IOP values were significantly lower in the Latanoprost group than in the Unoprostone group (p=0.023). Regarding the 3-year cumulative survival rate of visual field loss progression, there were no significant differences between groups in any parameters of the visual field or guided progression analysis. There were no significant differences between groups in disc changes. CONCLUSIONS: No significant differences were found between groups with regard to the visual field and structural progression in patients with NTG, although unoprostone was less effective than latanoprost in lowering the IOP. Dove Medical Press 2017-09-01 /pmc/articles/PMC5589109/ /pubmed/28979091 http://dx.doi.org/10.2147/OPTH.S144344 Text en © 2017 Takemoto et al. This work is published and licensed by Dove Medical Press Limited The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed.
spellingShingle Original Research
Takemoto, Daisuke
Higashide, Tomomi
Saito, Yoshiaki
Ohkubo, Shinji
Udagawa, Sachiko
Takeda, Hisashi
Sugiyama, Kazuhisa
Intraocular pressure and visual field changes in normal-tension glaucoma patients treated using either unoprostone or latanoprost: a prospective comparative study
title Intraocular pressure and visual field changes in normal-tension glaucoma patients treated using either unoprostone or latanoprost: a prospective comparative study
title_full Intraocular pressure and visual field changes in normal-tension glaucoma patients treated using either unoprostone or latanoprost: a prospective comparative study
title_fullStr Intraocular pressure and visual field changes in normal-tension glaucoma patients treated using either unoprostone or latanoprost: a prospective comparative study
title_full_unstemmed Intraocular pressure and visual field changes in normal-tension glaucoma patients treated using either unoprostone or latanoprost: a prospective comparative study
title_short Intraocular pressure and visual field changes in normal-tension glaucoma patients treated using either unoprostone or latanoprost: a prospective comparative study
title_sort intraocular pressure and visual field changes in normal-tension glaucoma patients treated using either unoprostone or latanoprost: a prospective comparative study
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5589109/
https://www.ncbi.nlm.nih.gov/pubmed/28979091
http://dx.doi.org/10.2147/OPTH.S144344
work_keys_str_mv AT takemotodaisuke intraocularpressureandvisualfieldchangesinnormaltensionglaucomapatientstreatedusingeitherunoprostoneorlatanoprostaprospectivecomparativestudy
AT higashidetomomi intraocularpressureandvisualfieldchangesinnormaltensionglaucomapatientstreatedusingeitherunoprostoneorlatanoprostaprospectivecomparativestudy
AT saitoyoshiaki intraocularpressureandvisualfieldchangesinnormaltensionglaucomapatientstreatedusingeitherunoprostoneorlatanoprostaprospectivecomparativestudy
AT ohkuboshinji intraocularpressureandvisualfieldchangesinnormaltensionglaucomapatientstreatedusingeitherunoprostoneorlatanoprostaprospectivecomparativestudy
AT udagawasachiko intraocularpressureandvisualfieldchangesinnormaltensionglaucomapatientstreatedusingeitherunoprostoneorlatanoprostaprospectivecomparativestudy
AT takedahisashi intraocularpressureandvisualfieldchangesinnormaltensionglaucomapatientstreatedusingeitherunoprostoneorlatanoprostaprospectivecomparativestudy
AT sugiyamakazuhisa intraocularpressureandvisualfieldchangesinnormaltensionglaucomapatientstreatedusingeitherunoprostoneorlatanoprostaprospectivecomparativestudy